25 сент. 2024 г. · Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced bleeding and stable factor IX ...

26 сент. 2024 г. · Fidanacogene elaparvovec was superior to prophylaxis for the treatment of participants with hemophilia B, leading to reduced bleeding and stable factor IX ...

26 апр. 2024 г. · BEQVEZ is a one-time treatment that is designed to enable people living with hemophilia B to produce FIX themselves rather than the current standard of care.

25 сент. 2024 г. · Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71 percent after a single infusion of gene therapy.

31 мая 2024 г. · Results show that Durveqtix substantially reduces the frequency of bleeding compared to standard care. ABR was 1.44 for fidanacogene elaparvovec ...

9 окт. 2024 г. · #VisualAbstract: Gene Therapy with Fidanacogene Elaparvovec in Adults with Hemophilia B is Superior to Prophylaxis. byAstrid Bradshawand ...

30 апр. 2024 г. · With the approval of fidanacogene elaparvovec, it is hoped that patients with hemophilia B will have access to a promising therapeutic option ...

26 апр. 2024 г. · Fidanacogene elaparvovec is a one-time therapy designed to enable those with hemophilia B to produce their own FIX, while the current standard ...

Health-related quality of life improvements in adults with haemophilia B after gene transfer with fidanacogene elaparvovec. Jan 2020; 125.

27 сент. 2024 г. · Adults with hemophilia B saw their number of bleeding episodes drop by an average of 71% after a single infusion of gene therapy.